Theratechnologies (TSE:TH) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Theratechnologies has announced an FDA review date for its new tesamorelin formulation, F8, set for March 2025. If approved, this formulation will replace the current F4 version and enjoys patent protection in the U.S. until 2033. The development could impact the company’s stock performance, attracting investor attention.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
